Amendment: SEC Form SC 13G/A filed by DENTSPLY SIRONA Inc.
$XRAY
Medical/Dental Instruments
Health Care
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/7/2024 | Outperform → Market Perform | Leerink Partners | |
| 10/25/2024 | $34.00 → $29.00 | Buy | Needham |
| 8/20/2024 | $34.00 | Buy | Needham |
| 2/26/2024 | $42.00 | Outperform | Leerink Partners |
| 11/16/2023 | $35.00 | Buy | Needham |
| 11/10/2023 | Mkt Perform → Outperform | William Blair | |
| 1/12/2023 | Underperform → Mkt Perform | William Blair | |
| 8/5/2022 | Mkt Perform → Underperform | William Blair |
SC 13G - DENTSPLY SIRONA Inc. (0000818479) (Subject)
SC 13G - DENTSPLY SIRONA Inc. (0000818479) (Subject)
SC 13G/A - DENTSPLY SIRONA Inc. (0000818479) (Subject)
Net sales of $951 million increased 0.5%, organic sales increased 1.3%GAAP gross margin of 52.1%, GAAP net loss of ($494) million or loss per share of ($2.46)Adjusted EBITDA margin of 17.9%, adjusted EPS of $0.50Revised FY24 outlook: expect organic sales of (3.5%) to (2.5%) (previously (1%) to flat); adjusted EPS of $1.82 to $1.86 (previously $1.96 to $2.02) CHARLOTTE, N.C., Nov. 07, 2024 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. ("Dentsply Sirona" or the "Company") (NASDAQ:XRAY) today announced its financial results for the third quarter of 2024. Third quarter net sales of $951 million increased 0.5% (organic sales increased 1.3%) compared to the third quarter
CHARLOTTE, N.C., Oct. 25, 2024 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. ("Dentsply Sirona" or the "Company") (NASDAQ:XRAY) today announced it will host a conference call to discuss its Byte Aligner business. Dentsply Sirona's management team will host an investor conference call and live webcast on October 25, 2024, at 9:00 am ET. For those planning to participate on the call, please register at https://register.vevent.com/register/BI91fb506c8c2944bca6e65629062dd357. A webcast replay of the conference call will be available on the Investors section of the Company's website following the call. About Dentsply Sirona Dentsply Sirona is the world's largest manufacturer of professional
Voluntarily Suspends Sales and Marketing of Byte Aligners and Impression Kits Provides Select Preliminary Third Quarter 2024 Results CHARLOTTE, N.C., Oct. 24, 2024 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. ("Dentsply Sirona" or the "Company") (NASDAQ:XRAY), today announced the voluntary suspension of sales and marketing of its Byte Aligners and Impression Kits while the Company conducts a review of certain regulatory requirements related to these products. The Company's decision was made in consultation with the U.S. Food and Drug Administration (FDA). In connection with this review, and Dentsply Sirona's proactive efforts to continuously improve its processes, the Comp
4 - DENTSPLY SIRONA Inc. (0000818479) (Issuer)
4 - DENTSPLY SIRONA Inc. (0000818479) (Issuer)
4 - DENTSPLY SIRONA Inc. (0000818479) (Issuer)
Baird analyst Jeffrey Johnson maintains Dentsply Sirona (NASDAQ:XRAY) with a Neutral and lowers the price target from $33 to $31.
In the preceding three months, 10 analysts have released ratings for Dentsply Sirona (NASDAQ:XRAY), presenting a wide array of perspectives from bullish to bearish. The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 1 5 4 0 0 Last 30D 0 0 1 0 0 1M Ago 0 3 0 0 0 2M Ago 0 0 0 0 0 3M Ago 1 2 3 0 0 Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $32.5, a high estimate of $38.00, and a low estimate of $27.00. Observing
Stifel analyst Jonathan Block maintains Dentsply Sirona (NASDAQ:XRAY) with a Hold and lowers the price target from $30 to $28.
Net sales of $951 million increased 0.5%, organic sales increased 1.3%GAAP gross margin of 52.1%, GAAP net loss of ($494) million or loss per share of ($2.46)Adjusted EBITDA margin of 17.9%, adjusted EPS of $0.50Revised FY24 outlook: expect organic sales of (3.5%) to (2.5%) (previously (1%) to flat); adjusted EPS of $1.82 to $1.86 (previously $1.96 to $2.02) CHARLOTTE, N.C., Nov. 07, 2024 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. ("Dentsply Sirona" or the "Company") (NASDAQ:XRAY) today announced its financial results for the third quarter of 2024. Third quarter net sales of $951 million increased 0.5% (organic sales increased 1.3%) compared to the third quarter
CHARLOTTE, N.C., Oct. 25, 2024 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. ("Dentsply Sirona" or the "Company") (NASDAQ:XRAY) today announced it will host a conference call to discuss its Byte Aligner business. Dentsply Sirona's management team will host an investor conference call and live webcast on October 25, 2024, at 9:00 am ET. For those planning to participate on the call, please register at https://register.vevent.com/register/BI91fb506c8c2944bca6e65629062dd357. A webcast replay of the conference call will be available on the Investors section of the Company's website following the call. About Dentsply Sirona Dentsply Sirona is the world's largest manufacturer of professional
Voluntarily Suspends Sales and Marketing of Byte Aligners and Impression Kits Provides Select Preliminary Third Quarter 2024 Results CHARLOTTE, N.C., Oct. 24, 2024 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. ("Dentsply Sirona" or the "Company") (NASDAQ:XRAY), today announced the voluntary suspension of sales and marketing of its Byte Aligners and Impression Kits while the Company conducts a review of certain regulatory requirements related to these products. The Company's decision was made in consultation with the U.S. Food and Drug Administration (FDA). In connection with this review, and Dentsply Sirona's proactive efforts to continuously improve its processes, the Comp
10-Q - DENTSPLY SIRONA Inc. (0000818479) (Filer)
8-K - DENTSPLY SIRONA Inc. (0000818479) (Filer)
8-K - DENTSPLY SIRONA Inc. (0000818479) (Filer)
4 - DENTSPLY SIRONA Inc. (0000818479) (Issuer)
4 - DENTSPLY SIRONA Inc. (0000818479) (Issuer)
4 - DENTSPLY SIRONA Inc. (0000818479) (Issuer)
Leerink Partners downgraded Dentsply Sirona from Outperform to Market Perform
Needham reiterated coverage of Dentsply Sirona with a rating of Buy and set a new price target of $29.00 from $34.00 previously
Needham reiterated coverage of Dentsply Sirona with a rating of Buy and set a new price target of $34.00
Credo Technology Group Holding Ltd ("Credo" or the "Company") (NASDAQ:CRDO), an innovator in providing secure, high-speed connectivity solutions that deliver improved power efficiency as data rates and corresponding bandwidth requirements increase throughout the data infrastructure market, today announced the appointment of Clyde Hosein to the Company's board of directors effective April 3, 2024. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240401894812/en/Credo Technology Group Holding Ltd Announces Appointment of Industry Veteran Clyde Hosein to Board of Directors (Photo: Business Wire) "Clyde's appointment to the Credo boar
NEW YORK, March 27, 2024 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P 500, S&P MidCap 400 and S&P SmallCap 600: Solventum Corp. (NYSE:SOLV) will be added to the S&P 500 effective prior to the open of trading on Monday, April 1, replacing V.F. Corp. (NYSE:VFC), which will be moved to the S&P SmallCap 600 effective prior to the open of trading on Wednesday, April 3. V.F. will replace ModivCare Inc. (NASD: MODV) in the S&P SmallCap 600 also effective prior to the open of trading on April 3. S&P 500 and 100 constituent 3M Co. (NYSE:MMM) is spinning off Solventum in a transaction expected to be completed April 1. Following the spin-off, the parent 3M will rema
CHARLOTTE, N.C., Feb. 29, 2024 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. ("Dentsply Sirona" or the "Company") (NASDAQ:XRAY) today announced that Eric K. Brandt, who has served as a Director on the Company's Board of Directors (the "Board") for nearly twenty years and as Chairman of the Board for six years, has informed the Board of his intention to retire at the May 2024 annual meeting and that he will not be standing for re-election. Mr. Brandt commented, "As I think back on the past two decades and all of the challenges we've navigated together, I am grateful for the talented and dedicated individuals with whom I have had the privilege to serve. I am proud of the strong and diverse Boar